GenSight Biologics S.A. (SIGHT.PA) Stock Price
€0.164 0%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
2 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on GenSight Biologics S.A., AI stock picks, stock alerts and much more.
SIGHT.PA AI Stock Analysis
AI stock analysis for SIGHT.PA is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like GenSight Biologics S.A. (SIGHT.PA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
GenSight Biologics S.A. (SIGHT.PA) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of GenSight Biologics S.A. (SIGHT.PA), currently trading at €0.164, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About SIGHT.PA
-
GenSight Biologics S.
-
Symbol
SIGHT.PA
-
Market
EURONEXT
-
Industry
Biotechnology
-
Market Cap
25.3M
Similar Stocks
 |
Valneva SE VLA.PA |
€5.05 2.4% |
5 |
 |
Financière de Tubize SA TUB.BR |
€160.6 0.4% |
8 |
 |
OSE Immunotherapeutics SA OSE.PA |
€6.32 0.5% |
6 |
 |
UCB SA UCB.BR |
€197.3 0.9% |
6 |
 |
Innate Pharma S.A. IPH.PA |
€2.01 1.9% |
5 |
SIGHT.PA Alternative Data
Web Traffic
GenSight Biologics S.A. receives an estimated 4631 monthly visitors to gensight-biologics.com.
-
Web Traffic
4631
-
Change from Previous Month
126.1%
-
3 Month Change
60%
-
YoY Change
60%
Twitter Followers
GenSight Biologics S.A. has 1,670 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.3% over the last month.
-
Twitter Followers
1670
-
Daily Change
0.1%
-
1 Month Change
0.3%
-
3 Month Change
0.4%
LinkedIn Followers
9,126 are following GenSight Biologics S.A. on LinkedIn, up by 0.7% over the last month.
-
LinkedIn Followers
9126
-
Daily Change
0.7%
-
1 Month Change
0.7%
-
3 Month Change
2.5%
LinkedIn Employees
According to LinkedIn, GenSight Biologics S.A. has 33 employees, down by -2.9% over the last month.
-
LinkedIn Employees
33
-
Daily Change
2.9%
-
1 Month Change
2.9%
-
3 Month Change
2.9%
News Mentions
GenSight Biologics S.A. was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
GenSight Biologics S.A. has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
1 Month Change
0%
-
3 Month Change
0%
SIGHT.PA Financials
SIGHT.PA Key Metrics
-
Total Revenue
€897K
-
Net Income
-€8.2M
-
Earnings per Share
-€0.0749
-
Free cash flow
-€5.6M
-
EBITDA
-€7.4M
-
EBITDA Ratio
-8.26421
-
Total Assets
€10.8M
SIGHT.PA 2-year Revenue & Income
SIGHT.PA 2-year Free Cash Flow
SIGHT.PA Technicals
SIGHT.PA SMA
SIGHT.PA RSI
FAQ
What's the current price of GenSight Biologics S.A. (SIGHT.PA) Stock?
The price of an GenSight Biologics S.A. (SIGHT.PA) share is €0.164.
What's the market cap of GenSight Biologics S.A.?
The current market cap of GenSight Biologics S.A. is 25.3M.
Should I buy or sell SIGHT.PA?
GenSight Biologics S.A. shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, GenSight Biologics S.A. is better viewed as a hold or accumulate position while waiting for further developments.
Is GenSight Biologics S.A. a good investment?
The current analysis of GenSight Biologics S.A.'s fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in GenSight Biologics S.A.'s portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy GenSight Biologics S.A. (SIGHT.PA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for GenSight Biologics S.A. stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to GenSight Biologics S.A. (SIGHT.PA) that investors often compare it to?
GenSight Biologics S.A. (SIGHT.PA) is often compared to similar stocks such as Valneva SE, Financière de Tubize SA, OSE Immunotherapeutics SA, UCB SA and Innate Pharma S.A..
What is the forecast for GenSight Biologics S.A.'s stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast GenSight Biologics S.A.'s stock price to be around €0.162 in 2026. Starting from the current price of €0.164, this represents a 1.2% change in price, indicating a neutral outlook for the stock.
How to buy GenSight Biologics S.A. (SIGHT.PA) Stock?
GenSight Biologics S.A. stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy GenSight Biologics S.A. shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.